Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 21M | 24M | 20M | 19M | 21M |
| Gross Profit | 6M | 10M | 7M | 6M | 6M |
| Operating Income | 608K | 4M | 3M | 2M | 3M |
| EBITDA | 933K | 4M | 3M | 3M | 3M |
| Net Income | 1M | 4M | 3M | 3M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.48
+2.48% today
1Y Change
-82.25%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Jin Medical International Ltd. (ZJYL) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $2.48 and down 82.2% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of -12.0%, EPS growth of -68.1%, a dividend yield of 0.0%. What stands out right now is revenue -12.0%, EPS -68.1%, free cash flow -59.8% with operating margin 2.9% and ROIC 1.1%. Valuation is more restrained than many high-expectation growth names at P/E 16.4 and price/sales 0.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZJYL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZJYL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZJYL Max Drawdown
-89.18%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZJYL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$20.8M
+8.2% YoY
FY Net Income
$2.6M
-2.8% YoY
Free Cash Flow
$5.8M
+276.5% YoY
Revenue Growth
-12.0%
EPS Growth
-68.1%
Gross Margin
29.8%
Net Margin
5.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 21M | 24M | 20M | 19M | 21M |
| Gross Profit | 6M | 10M | 7M | 6M | 6M |
| Operating Income | 608K | 4M | 3M | 2M | 3M |
| EBITDA | 933K | 4M | 3M | 3M | 3M |
| Net Income | 1M | 4M | 3M | 3M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 8M | 7M | 5M | 4M |
| Total Assets | 53M | 46M | 33M | 21M | 22M |
| Total Liabilities | 24M | 17M | 9M | 6M | 8M |
| Shareholder Equity | 30M | 29M | 24M | 15M | 14M |
| Total Debt | 19M | 12M | 4M | 0 | 0 |
| Net Debt | 11M | 3M | -3M | -5M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+269.7% YoY
Capital Expenditures
43K
-6.8% YoY
Free Cash Flow
6M
+276.5% YoY
Key ratios
Gross Margin
29.8%
Operating Margin
2.9%
Net Margin
5.8%
ROE
4.1%
Debt / Equity
0.64x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.